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Cancer stem cells may be important targets for new anticancer drugs. In two recent articles inCell Stem Cell,
Jin et al. (2009) and Hoey et al. (2009) provide proof of principle for this idea in experimental models of solid
tumors and leukemias, respectively.The development of disease-specific an-
ticancer drugs is advancing the treat-
ment of many malignancies (Weiner et al.,
2009). These new therapeutics have been
designed to target proteins expressed by
tumor cells and are thought to be equally
toxic to all cells within an individual
cancer. Their specificity for malignant
cells and hence toxicity to normal tissues
varies from tumor to tumor.
However, all cells within a cancer may
not be functionally equivalent. Evidence
for tumor cell heterogeneity emerged in
the 1960s (e.g., Bruce and van der Gaag,
1963) and was crystallized in the 1990s
by the studies of Dick and others (Dick,
2008). The hypothesis of ‘‘tumor-propa-
gating’’ or ‘‘cancer stem’’ cells (CSCs)
suggests that tumor growth is maintained
by a subpopulation of cells exhibiting the
cardinal stem cell properties of self-
renewal and a capacity for differentiation.
CSCs are thought to sit at the apex of
a cellular hierarchy within a tumor and
may be responsible for disease initiation
and for relapse. By analogy with normal
hematopoietic stem cells, they are pre-
dicted to be relatively quiescent and resis-
tant to conventional chemotherapy. Thus,
CSCsare the cells to target for the efficient
treatment of cancer.
Human CSCswere originally character-
ized by a combination of their immuno-
phenotype and ability to reconstitute
whole tumors after serial xenotransplanta-
tion into sublethally irradiated immunode-
ficient NOD/SCID mice. They were
thought to be rare cells, but studies with
recipient hosts lacking NK cell activity
(e.g., NOD/SCID IL2Rgnull) suggested
that cells with CSC potential exist at
much higher frequencies in many malig-
nancies, with a range of immunopheno-
types (Quintana et al., 2008; LeViseur
et al., 2008). Additionally, for leukemiasat least, there is variability in the capacities
of individual bulk tumors to reconstitute
the disease. Although such observations
may merely expose the immunological
limitations of xenografting, another expla-
nation could be that CSCs are heteroge-
neous with varying intrinsic capacities for
self-renewal and differentiation.
Such experimental complexities and
the apparent heterogeneity of cells with
CSC properties have hindered the identi-
fication of specific markers that reliably
identify the CSC subset. Nevertheless,
the capacity of CSCs to replicate the
heterogeneity of tumors provides an im-
portant preclinical model in which new
therapies can be tested (Jordan, 2009).
Two recent papers in Cell Stem Cell
provide important experimental evidence
for the merit of CSC targeting. In this
issue, Hoey et al. (2009) demonstrate a
reduction of CSC function by an inhibitor
of notch activity. The authors developed
a neutralizing antibody against delta like
4 ligand (DLL4), a membrane-associated
notch ligand. The notch pathway has
been implicated in intestinal cell homeo-
stasis (Radtke and Clevers, 2005), and
many cancers express DLL4. In a NOD/
SCID model of human colon cancer,
they show that administration of anti-
DLL4 reduces tumor growth in recipient
mice and reduces tumor engraftment in
secondary recipients, implying an impact
on CSC self-renewal. The authors also
raise the possibility of using their antibody
in combination with a widely used chemo-
therapeutic, irinotecan.
The second paper in Cell Stem Cell (in
theJuly issue)by Jin et al. (2009) describes
immunotherapy targeting acute myeloid
leukemia stem cells (AML-LSCs) isolated
from clinical samples. The authors exploit
the observation that AML-LSCs (defined
byNOD/SCIDengraftment) but not normalCell Stem Cehematopoietic stem cells exhibit high
expression of the IL3 receptor (CD123).
Administration of the CD123 antibody
7G3 inhibits the engraftment of AML-
LSCs in NOD/SCID mice. The authors
find that secondary transplantation of
AML is diminished if the primary recipients
have also received 7G3, suggesting that
the self-renewal potential of AML-LSCs
is impacted. They also report that 7G3
has little effect on normal hematopoietic
stem cell activity, implying some speci-
ficity for AML-LSC self-renewal. In analo-
gous experiments to those of Hoey et al.
(2009), the authors observe synergism of
7G3 when used in combination with cyto-
sine arabinoside. Interestingly, the effects
of 7G3are attenuatedwhen theassays are
performed in NOD/SCID IL2Rgnull recipi-
ents. This observation may reflect hetero-
geneity in the capacity of cells within the
AML-LSC compartment for tumor propa-
gation and self-renewal. Alternatively, or
in addition, it may indicate a dependence
of the 7G3 effect on extrinsic NK activity
in xenograft models.
These studies establish the principle
that the self-renewal capacities inherent
in CSCs can be targeted with therapeutic
intent by monoclonal antibodies. They
also demonstrate that such antibodies
synergize with standard drugs. Although
it is to be hoped that these exciting find-
ings make their way to the bedside,
important questions remain unanswered.
Just what the CSC hypothesis means
for cancer medicine is unclear. The field
is in its infancy and correlations between
CSC activity and clinical outcome are
the focus of much interest. The main
clinical problem is disease relapse after
initial responses to treatment. Most
CSCs have been isolated from untreated
clinical samples. Perhaps the pertinent
therapeutic targets are those cells thatll 5, August 7, 2009 ª2009 Elsevier Inc. 125
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Previewsremain after (or have been selected by)
treatment.
A prevailing view of carcinogenesis is of
a stepwise accumulation of transforming
genetic changes that arise in the progeny
of an initially normal cell that has been
exposed to some mutagenizing event.
This ‘‘linear progression’’ of sequentially
more mutated progeny is thought to
culminate in a cell capable of sustaining
the cancer (the CSC).
However, the variability in tumor-initi-
ating capacities observed when the
various cellular compartments of pretreat-
ment cancer tissues are tested in
different mouse recipients could imply
that cells capable of sustaining cancer
are heterogeneous and that multiple
subclones capable of tumor initiation arise
in parallel (as opposed to a strict linear
evolution) and compete for dominance
in a Darwinian fashion. Molecular genetic
evidence for such heterogeneity has
come from the study of lymphoid malig-
nancies where global sequencing ex-
poses molecular variability within indi-
vidual tumors, suggesting that they are
comprised of interrelated subclones de-
rived from common ancestors (Campbell
et al., 2008). Those clones that win theUnraveling the Hu
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The human embryonic stem cell (hES
tion is available. In this issue of Cell
phosphoproteome and its changes
Human embryonic stem cells (hESCs) are
capable of differentiation into all lineages
of the body, but directed differentiation
to pure populations of cells has proven
difficult to accomplish. Ideally, hESCs
could be coerced to a particular lineage
by making a series of changes to their
126 Cell Stem Cell 5, August 7, 2009 ª2009initial battle of selection during carcino-
genesis may not be the ones that
survive/are selected by chemotherapy
and which drive relapse.
Circumstantial evidence for the emer-
gence of relapse propagating clones
(RPCs) has come from single-nucleotide
polymorphism studies of paired diag-
nostic and relapse samples from patients
with childhood leukemia (Mullighan et al.,
2008). Here, the genetic abnormalities
that were dominant at the time of disease
relapse often differed from those detected
at presentation, when they represented
a minor component of the disease.
The functional andmolecular character-
ization of RPCs would be subject to the
same limitations as for CSCs and would
additionally require diligent archiving of
matched diagnostic, remission, and re-
lapse material.
This notion serves to underline the fact
that patients represent the best ‘‘test
tubes’’ for such work and may point the
way forward for this fascinating field.
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